Allogeneic transplantation for Hodgkin's lymphoma

British Journal of Haematology

Volumn 152, Issue 3, 2011, Pages 261-272

  Corradini, Paolo ^a,b   Sarina, Barbara ^c   Farina, Lucia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Allogeneic; Hodgkin's lymphoma; Reduced intensity

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTIBODY CONJUGATE; BRENTUXIMAB VEDOTIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; EPSTEIN BARR VIRUS ANTIGEN; ETOPOSIDE; FLUDARABINE; GIVINOSTAT; HISTONE DEACETYLASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MECLORETHAMINE; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; SGN 35; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ALLOTRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOTOXIC T LYMPHOCYTE; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE FREE INTERVAL; DONOR LYMPHOCYTE INFUSION; DONOR SELECTION; DRUG EFFICACY; EPSTEIN BARR VIRUS; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HODGKIN DISEASE; HUMAN; LYMPHOPROLIFERATIVE DISEASE; MORTALITY; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR CELL; WHOLE BODY RADIATION;

GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; PATIENT SELECTION; TRANSPLANTATION CONDITIONING;

EID: 78651370777     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08492.x     Document Type: Review

References (81)

1. Akpek, G., Ambinder, R.F., Piantadosi, S., Abrams, R.A., Brodsky, R.A., Vogelsang, G.B., Zahurak, M.L., Fuller, D., Miller, C.B., Noga, S.J., Fuchs, E., Flinn, I.W., O'Donnell, P., Seifter, E.J., Mann, R.B. & Jones, R.J. (2001) Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. Journal of Clinical Oncology, 19, 4314-4321.
2. Aldinucci, D., Gloghini, A., Pinto, A., De Filippi, R. & Carbone, A. (2010) The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. Journal of Pathology, 221, 248-263.
3. Alvarez, I., Sureda, A., Caballero, M.D., Urbano-Ispizua, A., Ribera, J.M., Canales, M., García-Conde, J., Sanz, G., Arranz, R., Bernal, M.T., de la Serna, J., Díez, J.L., Moraleda, J.M., Rubió-Félix, D., Xicoy, B., Martínez, C., Mateos, M.V. & Sierra, J. (2006) Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol. Biology of Blood and Marrow Transplantation, 12, 172-183.
4. Anderlini, P., Saliba, R., Acholonu, S., Giralt, S.A., Andersson, B., Ueno, N.T., Hosing, C., Khouri, I.F., Couriel, D., de Lima, M., Qazilbash, M.H., Pro, B., Romaguera, J., Fayad, L., Hagemeister, F., Younes, A., Munsell, M.F. & Champlin, R.E. (2008) Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica, 93, 257-264.
5. Anderson, J.E., Litzow, M.R., Appelbaum, F.R., Schoch, G., Fisher, L.D., Buckner, C.D., Petersen, F.B., Crawford, S.W., Press, O.W. & Sanders, J.E. (1993) Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. Journal of Clinical Oncology, 11, 2342-2350.
6. Appelbaum, F.R., Sullivan, K.M., Thomas, E.D., Buckner, C.D., Clift, R.A., Deeg, H.J., Neiman, P.E., Sanders, J.E., Stewart, P. & Storb, R. (1985) Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease. Journal of Clinical Oncology, 3, 1490-1494.
7. Bolwell, B.J., Kalaycio, M., Goormastic, M., Dannley, R., Andresen, S.W., Lichtin, A., Overmoyer, B. & Pohlman, B. (1997) Progressive disease after ABMT for Hodgkin's disease. Bone Marrow Transplantation, 20, 761-765.
8. Bonfante, V., Santoro, A., Viviani, S., Valagussa, P. & Bonadonna, G. (1992) ABVD in the treatment of Hodgkin's disease. Seminars of Oncology, 19, 38-44.
9. Burger, J.A., Ghia, P., Rosenwald, A. & Caligaris-Cappio, F. (2009) The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood, 114, 3367-3375.
10. Burroughs, L.M., O'Donnell, P.V., Sandmaier, B.M., Storer, B.E., Luznik, L., Symons, H.J., Jones, R.J., Ambinder, R.F., Maris, M.B., Blume, K.G., Niederwieser, D.W., Bruno, B., Maziarz, R.T., Pulsipher, M.A., Petersen, F.B., Storb, R., Fuchs, E.J. & Maloney, D.G. (2008) Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biology of Blood and Marrow Transplantation, 14, 1279-1287.
11. Carella, A.M., Cavaliere, M., Lerma, E., Ferrara, R., Tedeschi, L., Romanelli, A., Vinci, M., Pinotti, G., Lambelet, P., Loni, C., Verdiani, S., De Stefano, F., Valbonesi, M. & Corsetti, M.T. (2000) Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. Journal of Clinical Oncology, 18, 3918-3924.
12. Carlo-Stella, C., Guidetti, A., Viviani, S., Bonfante, V., Valagussa, P., Marchianò, A., Crippa, F., Zambelli, S., Fasola, C., Corradini, P., Tarella, C., Di Nicola, M. & Gianni, A.M. (2008) Phase II Trial of combination of the histone deacetylase inhibitor ITF2357 and meclorethamine demonstrates clinical activity and safety in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma (HL). Blood, 112, 2586a. (Abstract).
13. Castagna, L., Bramanti, S., Balzarotti, M., Sarina, B., Todisco, E., Anastasia, A., Magagnoli, M., Mazza, R., Nozza, A., Giordano, L., Rodari, M., Rinifilo, E., Chiti, A. & Santoro, A. (2009b) Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. British Journal of Haematology, 145, 369-372.
14. Castagna, L., Sarina, B., Todisco, E., Magagnoli, M., Balzarotti, M., Bramanti, S., Mazza, R., Anastasia, A., Bacigalupo, A., Aversa, F., Soligo, D., Giordano, L. & Santoro, A. (2009a) Allogeneic stem cell transplantation compared with chemotherapy for poor-risk Hodgkin lymphoma. Biology of Blood and Marrow Transplantation, 15, 432-438.
15. Chantrain, C.F., Feron, O., Marbaix, E. & DeClerck, Y.A. (2008) Bone marrow microenvironment and tumor progression. Cancer Microenvironment, 1, 23-35.
16. Constans, M., Sureda, A., Terol, M.J., Arranz, R., Caballero, M.D., Iriondo, A., Jarque, I., Carreras, E., Moraleda, J.M., Carrera, D., León, A., López, A., Albó, C., Díaz-Mediavilla, J., Fernández-Abellán, P., García-Ruiz, J.C., Hernández-Navarro, F., Mataix, R., Petit, J., Pascual, M.J., Rifón, J., García-Conde, J., Fernández-Rañada, J.M., Mateos, M.V., Sierra, J. & Conde, E.; G.E.L/.T.A.M.O.Cooperative.Group. (2003) Autologous stem cell transplantation for primary refractory Hodgkin's disease: results and clinical variables affecting outcome. Annals of Oncology, 14, 745-751.
17. Corradini, P. & Farina, L. (2005) Immune-mediated attack in relapsed Hodgkin's lymphoma. Lancet, 365, 1906-1908.
18. Corradini, P., Dodero, A., Farina, L., Fanin, R., Patriarca, F., Miceli, R., Matteucci, P., Bregni, M., Scimè, R., Narni, F., Pogliani, E., Locasciulli, A., Milani, R., Carniti, C., Bacigalupo, A., Rambaldi, A., Bonifazi, F., Olivieri, A., Gianni, A.M., Tarella, C. & Gruppo Italiano Trapianto di Midollo Osseo. (2007) Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia, 21, 2316-2323.
19. Corradini, P., Dodero, A., Farina, L., Fanin, R., Patriarca, F., Miceli, R., Matteucci, P., Ciceri, F., Scime', R., Narni, F., Pogliani, E., Locasciulli, A., Dalto, S., Carniti, C., Bacigalupo, A., Rambaldi, A., Bonifazi, F., Olivieri, A., Brune, M.L., Gianni, A.M. & Tarella, C. (2008) Long-Term Follow-up of Patients Affected by Relapsed Lymphomas Receiving Reduced-Intensity Conditioning (RIC) Regimen Followed by Allogeneic Stem Cell Transplantation (Allo-SCT): An Update of the Phase II Study of the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). Blood, 112, 3303a. (Abstract).
20. Crocchiolo, R., Fallanca, F., Giovacchini, G., Ferreri, A.J., Assanelli, A., Verona, C., Pescarollo, A., Bregni, M., Ponzoni, M., Gianolli, L., Fazio, F. & Ciceri, F. (2009) Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma. Annals of Hematology, 88, 1229-1236.
21. Devetten, M.P., Hari, P.N., Carreras, J., Logan, B.R., van Besien, K., Bredeson, C.N., Freytes, C.O., Gale, R.P., Gibson, J., Giralt, S.A., Goldstein, S.C., Gupta, V., Marks, D.I., Maziarz, R.T., Vose, J.M., Lazarus, H.M. & Anderlini, P. (2009) Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biology of Blood and Marrow Transplantation, 15, 109-117.
22. Dickinson, M., Ritchie, D., DeAngelo, D.J., Spencer, A., Ottmann, O.G., Fischer, T., Bhalla, K.N., Liu, A., Parker, K., Scott, J.W., Bishton, M. & Prince, H.M. (2009) Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. British Journal of Haematology, 147, 97-101.
23. Diepstra, A., Poppema, S., Boot, M., Visser, L., Nolte, I.M., Niens, M., Te Meerman, G.J. & van den Berg, A. (2008) HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma. Tissue Antigens, 71, 219-226.
24. DiNardo, C.D. & Tsai, D.E. (2010) Treatment advances in posttransplant lymphoproliferative disease. Current Opinion in Hematology, 17, 368-374.
25. Dodero, A., Crocchiolo, R., Patriarca, F., Miceli, R., Castagna, L., Ciceri, F., Bramanti, S., Frungillo, N., Milani, R., Crippa, F., Fallanca, F., Englaro, E. & Corradini, P. (2010) Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation. Cancer, 116: 5001-5011, Jul 21. [Epub ahead of print].
26. Engert, A., Sureda, A., Chiattone, C., Buccheri, V., Ong, T.C., Ben-Yehuda, D., Myke, N., Shen, A., Le Corre, C. & Younes, A. (2010) Evidence of clinical acitivity in phase II study of oral panobinostat in patients with relapsed /refractory Hodgkin lymphoma (HL) after autologous hematopoietic stem cell transplant (AHSCT). Haematologica, 95(s2), 1147a. (Abstract).
27. Fanale, M., Bartlett, N.L., Forero-Torres, A., Rosenblatt, J., Horning, S.J., Franklin, A.R., Lynch, C.M., Sievers, E.L., Kennedy, D.A. & PharmD, B.C.O.P. (2009) The antibody-drug conjugate brentuximab vedotin (SGN-35) induced multiple objective responses in patients with relapsed or refractory CD30-positive lymphomas in a Phase 1 weekly dosing study. Blood, 114, 2731a. (Abstract).
28. Farina, L., Bruno, B., Patriarca, F., Spina, F., Sorasio, R., Morelli, M., Fanin, R., Boccadoro, M. & Corradini, P. (2009) The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia, 23, 1131-1138.
29. Faulkner, R.D., Craddock, C., Byrne, J.L., Mahendra, P., Haynes, A.P., Prentice, H.G., Potter, M., Pagliuca, A., Ho, A., Devereux, S., McQuaker, G., Mufti, G., Yin, J.L. & RusselL, N.H. (2004) BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. Blood, 103, 428-434.
30. Fermé, C., Mounier, N., Diviné, M., Brice, P., Stamatoullas, A., Reman, O., Voillat, L., Jaubert, J., Lederlin, P., Colin, P., Berger, F. & Salles, G. (2002) Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. Journal of Clinical Oncology, 20, 467-475.
31. Gajewski, J.L., Phillips, G.L., Sobocinski, K.A., Armitage, J.O., Gale, R.P., Champlin, R.E., Herzig, R.H., Hurd, D.D., Jagannath, S., Klein, J.P., Lazarus, H.M., McCarthy, Jr, P.L., Pavlovsky, S., Peterson, F.B., Rowlings, P.A., Russell, J.A., Silver, S.M., Vose, J.M., Wiernik, P.H., Bortin, M.M. & Horowitz, M.M. (1996) Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. Journal of Clinical Oncology, 14, 572-578.
32. Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., Biggi, A., Vitolo, U., Stelitano, C., Sancetta, R., Trentin, L., Luminari, S., Iannitto, E., Viviani, S., Pierri, I. & Levis, A. (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. Journal of Clinical Oncology, 25, 3746-3752.
33. Huen, D.S., Henderson, S.A., Croom-Carter, D. & Rowe, M. (1995) The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene, 10, 549-560.
34. Jabbour, E., Hosing, C., Ayers, G., Nunez, R., Anderlini, P., Pro, B., Khouri, I., Younes, A., Hagemeister, F., Kwak, L. & Fayad, L. (2007) Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer, 109, 2481-2489.
35. Johnston, P.B., Inwards, D.J., Colgan, J.P., Laplant, B.R., Kabat, B.F., Habermann, T.M., Micallef, I.N., Porrata, L.F., Ansell, S.M., Reeder, C.B., Roy, V. & Witzig, T.E. (2010) A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. American Journal of Hematology, 85, 320-324.
36. Jones, R.J., Ambinder, R.F., Piantadosi, S. & Santos, G.W. (1991) Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood, 77, 649-653.
37. Josting, A., Rueffer, U., Franklin, J., Sieber, M., Diehl, V. & Engert, A. (2000) Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood, 96, 1280-1286.
38. Josting, A., Franklin, J., May, M., Koch, P., Beykirch, M.K., Heinz, J., Rudolph, C., Dieh, l.V. & Engert, A. (2002) New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. Journal of Clinical Oncology, 20, 221-230.
39. Josting, A., Rudolph, C., Mapara, M., Glossmann, J.P., Sieniawski, M., Sieber, M., Kirchner, H.H., Dörken, B., Hossfeld, D.K., Kisro, J., Metzner, B., Berdel, W.E., Diehl, V. & Engert, A. (2005) Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Annals of Oncology, 16, 116-123.
40. Kewalramani, T., Nimer, S.D., Zelenetz, A.D., Malhotra, S., Qin, J., Yahalom, J. & Moskowitz, C.H. (2003) Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's lymphoma. Bone Marrow Transplantation, 32, 673-679.
41. Koenecke, C., Ukena, S.N., Ganser, A. & Franzke, A. (2008) Regulatory T cells as therapeutic target in Hodgkin's lymphoma. Expert Opinion on Therapeutic Targets, 12, 769-782.
42. Küppers, R. (2009) Molecular biology of Hodgkin lymphoma. Hematology American Society of Hematology Educational Program, 1, 491-496.
43. Lavoie, J.C., Connors, J.M., Phillips, G.L., Reece, D.E., Barnett, M.J., Forrest, D.L., Gascoyne, R.D., Hogge, D.E., Nantel, S.H., Shepherd, J.D., Smith, C.A., Song, K.W., Sutherland, H.J., Toze, C.L., Voss, N.J. & Nevill, T.J. (2005) High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver. Blood, 106, 1473-1478.
44. Lazarus, H.M., Rowlings, P.A., Zhang, M.J., Vose, J.M., Armitage, J.O., Bierman, P.J., Gajewski, J.L., Gale, R.P., Keating, A., Klein, J.P., Miller, C.B., Phillips, G.L., Reece, D.E., Sobocinski, K.A., van Besien, K. & Horowitz, M.M. (1999) Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. Journal of Clinical Oncology, 17, 534-545.
45. Majhail, N.S., Weisdorf, D.J., Wagner, J.E., Defor, T.E., Brunstein, C.G. & Burns, L.J. (2006) Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen for advanced Hodgkin lymphoma. Blood, 107, 3804-3807.
46. Marshall, N.A., Christie, L.E., Munro, L.R., Culligan, D.J., Johnston, P.W., Barker, R.N. & Vickers, M.A. (2004) Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood, 103, 1755-1762.
47. Martinez, C., Canals, C., Castagna, C., Alessandrino, E., Karakasis, D., Milpied, N., Paola, A., Leone, G., Treney, M., Snowden, J., Kanfer, E., Bosi, A., Caselli, D., De Souza, C.A., Luan, J., Oneto, R., Willemze, R., Arranz, R., Jebavy, L., Hellmann, A., Gisselbrecht, C. & Sureda, A., on behalf of the GITMO and LWP of the EBMT. (2010) Outcome of patients with Hodgkin's lymphoma relapsing after autologous stem cell transplantation: comparison between reduced-intensity allogeneic stem cell transplantation and chemo-radiotherapy salvage approches. Bone Marrow Transplantation, 45, S252, 831a (Abstract).
48. Milpied, N., Fielding, A.K., Pearce, R.M., Ernst, P. & Goldstone, A.H. (1996) Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. Journal of Clinical Oncology, 14, 1291-1296.
49. Morschhauser, F., Brice, P., Fermé, C., Diviné, M., Salles, G., Bouabdallah, R., Sebban, C., Voillat, L., Casasnovas, O., Stamatoullas, A., Bouabdallah, K., André, M., Jais, J.P., Cazals-Hatem, D. & Gisselbrecht, C. (2008) Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. Journal of Clinical Oncology, 26, 5980-5987.
50. Moskowitz, A.J., Yahalom, J., Kewalramani, T., Maragulia, J.C., Vanak, J.M., Zelenetz, A.D. & Moskowitz, C.H. (2010) Pre-transplant functional imaging predicts outcome following autologous stem cell transplant for relapsed and refractory Hodgkin lymphoma. Blood, Aug 23 [Epub ahead of print].
51. Mueller, N., Evans, A., Harris, N.L., Comstock, G.W., Jellum, E., Magnus, K., Orentreich, N., Polk, B.F. & Vogelman, J. (1989) Hodgkin's disease and Epstein-Barr virus. Altered antibody pattern before diagnosis. New England Journal of Medicine, 320, 689-695.
52. Ocheni, S., Kroeger, N., Zabelina, T., Sobottka, I., Ayuk, F., Wolschke, C., Muth, A., Lellek, H., Petersen, L., Erttmann, R., Kabisch, H., Zander, A.R. & Bacher, U. (2008) EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplantation, 42, 181-186.
53. Papadopoulos, E.B., Ladanyi, M., Emanuel, D., Mackinnon, S., Boulad, F., Carabasi, M.H., Castro-Malaspina, H., Childs, B.H., Gillio, A.P. & Small, T.N. (1994) Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New England Journal of Medicine, 330, 1185-1191.
54. Peggs, K.S., Hunter, A., Chopra, R., Parker, A., Mahendra, P., Milligan, D., Craddock, C., Pettengell, R., Dogan, A., Thomson, K.J., Morris, E.C., Hale, G., Waldmann, H., Goldstone, A.H., Linch, D.C. & Mackinnon, S. (2005) Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet, 365, 1934-1941.
55. Peggs, K.S., Sureda, A., Qian, W., Caballero, D., Hunter, A., Urbano-Ispizua, A., Cavet, J., Ribera, J.M., Parker, A., Canales, M., Mahendra, P., Garcia-Conde, J., Milligan, D., Sanz, G., Thomson, K., Arranz, R., Goldstone, A.H., Alvarez, I., Linch, D.C., Sierra, J. & Mackinnon, S. (2007) Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. British Journal of Haematology, 139, 70-80.
56. Peniket, A.J., Ruiz de Elvira, M.C., Taghipour, G., Cordonnier, C., Gluckman, E., de Witte, T., Santini, G., Blaise, D., Greinix, H., Ferrant, A., Cornelissen, J., Schmitz, N., Goldstone, A.H.; European Bone Marrow Transplantation (EBMT) Lymphoma Registry. (2003) An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplantation, 31, 667-678.
57. Phillips, G.L., Reece, D.E., Barnett, M.J., Connors, J.M., Fay, J.W., Herzig, G.P., Herzig, R.H., Klingemann, H.G., Shepherd, J.D. & Wolff, S.N. (1989) Allogeneic marrow transplantation for refractory Hodgkin's disease. Journal of Clinical Oncology, 7, 1039-1045.
58. Robinson, S.P., Goldstone, A.H., Mackinnon, S., Carella, A., Russell, N., Taghipour, G., Schmitz, N. & de Elvira, C.R.; Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood, 100, 4310-4316.
59. Robinson, S.P., Sureda, A., Canals, C., Russell, N., Caballero, D., Bacigalupo, A., Iriondo, A., Cook, G., Pettitt, A., Socie, G., Bonifazi, F., Bosi, A., Michallet, M., Liakopoulou, E., Maertens, J., Passweg, J., Clarke, F., Martino, R., Schmitz, N.; Lymphoma Working Party of the EBMT. (2009) Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica, 94, 230-238.
60. Rooney, C.M., Roskrow, M.A., Suzuki, N., Ng, C.Y., Brenner, M.K. & Heslop, H. (1998) Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Annals of Oncology, 9(Suppl 5), S129-S132.
61. Sarina, B., Castagna, L., Farina, L., Patriarca, F., Benedetti, F., Carella, A.M., Falda, M., Guidi, S., Ciceri, F., Bonini, A., Ferrari, S., Malagola, M., Morello, E., Milone, G., Bruno, B., Mordini, N., Viviani, S., Levis, A., Giordano, L., Santoro, A., Corradini, P.; Gruppo Italiano Trapianto di Midollo Osseo. (2010) Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. Blood, 115, 3671-3677.
62. Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A.M., Haenel, M., Boissevain, F., Zschaber, R., Müller, P., Kirchner, H., Lohri, A., Decker, S., Koch, B., Hasenclever, D., Goldstone, A.H. & Diehl, V. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet, 359, 2065-2071.
63. Schot, B.W., Zijlstra, J.M., Sluiter, W.J., van Imhoff, G.W., Pruim, J., Vaalburg, W. & Vellenga, E. (2007) Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood, 109, 486-491.
64. Shamash, J., Lee, S.M., Radford, J.A., Rohatiner, A.Z., Chang, J., Morgenstern, G.R., Scarffe, J.H., Deakin, D.P. & Lister, T.A. (2000) Patterns of relapse and subsequent management following high-dose chemotherapy with autologous haematopoietic support in relapsed or refractory Hodgkin's lymphoma: a two centre study. Annals of Oncology, 11, 715-719.
65. Small, T.N., Papadopoulos, E.B., Boulad, F., Black, P., Castro-Malaspina, H., Childs, B.H., Collins, N., Gillio, A., George, D., Jakubowski, A., Heller, G., Fazzari, M., Kernan, N., MacKinnon, S., Szabolcs, P., Young, J.W. & O'Reilly, R.J. (1999) Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood, 93, 467-480.
66. Sorror, M.L., Maris, M.B., Storb, R., Baron, F., Sandmaier, B.M., Maloney, D.G. & Storer, B. (2005) Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood, 106, 2912-2919.
67. Sorror, M.L., Storer, B.E., Maloney, D.G., Sandmaier, B.M., Martin, P.J. & Storb, R. (2008) Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood, 111, 446-452.
68. Steidl, C., Lee, T., Shah, S.P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S.J., Iqbal, J., Weisenburger, D.D., Bast, M.A., Rosenwald, A., Muller-Hermelink, H.K., Rimsza, L.M., Campo, E., Delabie, J., Braziel, R.M., Cook, J.R., Tubbs, R.R., Jaffe, E.S., Lenz, G., Connors, J.M., Staudt, L.M., Chan, W.C. & Gascoyne, R.D. (2010) Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. New England Journal of Medicine, 362, 875-885.
69. Sureda, A., Constans, M., Iriondo, A., Arranz, R., Caballero, M.D., Vidal, M.J., Petit, J., López, A., Lahuerta, J.J., Carreras, E., García-Conde, J., García-Laraña, J., Cabrera, R., Jarque, I., Carrera, D., García-Ruiz, J.C., Pascual, M.J., Rifón, J., Moraleda, J.M., Pérez-Equiza, K., Albó, C., Díaz-Mediavilla, J., Torres, A., Torres, P., Besalduch, J., Marín, J., Mateos, M.V., Fernández-Rañada, J.M., Sierra, J. & Conde, E. (2005) Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Annals of Oncology, 16, 625-633.
70. Sureda, A., Robinson, S., Canals, C., Carella, A.M., Boogaerts, M.A., Caballero, D., Hunter, A.E., Kanz, L., Slavin, S., Cornelissen, J.J., Gramatzki, M., Niederwieser, D., Russell, N.H. & Schmitz, N. (2008) Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 26, 455-462.
71. Sureda, A., Canals, C., Arranz, R., Caballero, D., Ribera, J.M., Brune, M.L., Passweg, J.R., Besalduch, J., Duarte, R.F., Leon, A., Pascual, M.J. & Schmitz, N. (2009) Allogeneic Stem Cell Transplantation After Reduced Intensity Conditioning (RIC-allo) in Patients with Relapsed or Refractory Hodgkin's Lymphoma (HL). Final Analysis of the HDR-Allo Protocol - A Prospective Clinical Trial by the Grupo Español de Linfomas / Trasplante de Medula Osea (GEL/TAMO) and the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). Blood, 114, 658a. (abstract).
72. Sweetenham, J.W., Carella, A.M., Taghipour, G., Cunningham, D., Marcus, R., Della Volpe, A., Linch, D.C., Schmitz, N. & Goldstone, A.H. (1999) High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. Journal of Clinical Oncology, 17, 3101-3109.
73. Tarella, C., Cuttica, A., Vitolo, U., Liberati, M., Di Nicola, M., Cortelazzo, S., Rosato, R., Rosanelli, C., Di Renzo, N., Musso, M., Pavone, E., Santini, G., Pescarollo, A., De Crescenzo, A., Federico, M., Gallamini, A., Pregno, P., Romano, R., Coser, P., Gallo, E., Boccadoro, M., Barbui, T., Pileri, A., Gianni, A.M. & Levis, A. (2003) High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer, 97, 2748-2759.
74. Thomson, K.J., Peggs, K.S., Smith, P., Cavet, J., Hunter, A., Parker, A., Pettengell, R., Milligan, D., Morris, E.C., Goldstone, A.H., Linch, D.C. & Mackinnon, S. (2008) Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplantation, 41, 765-770.
75. Todisco, E., Congiu, A.S., Castagna, L., Nati, S., Giordano, L., Santoro, A. & Carella, A.M. (2010) Tandem autologous/reduced intensity allograft for relapsed/refractory Hodgkin's lymphoma: early allotransplant after intensive cytoreduction may maximize graft vs lymphoma effect? Haematologica, 95(s2), O879. (Abstract).
76. Tzankov, A., Meier, C., Hirschmann, P., Went, P., Pileri, S.A. & Dirnhofer, S. (2008) Correlation of high numbers of intratumoral FOXP3 + regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica, 93, 193-200.
77. Varterasian, M., Ratanatharathorn, V., Uberti, J.P., Karanes, C., Abella, E., Momin, F., Kasten-Sportes, C., Al-Katib, A., Lum, L. & Heilbrun, L.K. (1995) Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation. Leukemia and Lymphoma, 20, 59-65.
78. Viviani, S., Di Nicola, M., Bonfante, V., Di Stasi, A., Carlo-Stella, C., Matteucci, P., Magni, M., Devizzi, L., Valagussa, P. & Gianni, A.M. (2010) Long-term results of high-dose chemotherapy with autologous bone marrow or peripheral stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: a single institution experience. Leukemia and Lymphoma, 51, 1251-1259.
79. Vose, J.M., Bierman, P.J., Anderson, J.R., Kessinger, A., Pierson, J., Nelson, J., Frappier, B., Schmit-Pokorny, K., Weisenburger, D.D. & Armitage, J.O. (1992) Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood, 80, 2142-2148.
80. Weiss, L.M., Strickler, J.G., Warnke, R.A., Purtilo, D.T. & Sklar, J. (1987) Epstein-Barr viral DNA in tissues of Hodgkin's disease. American Journal of Pathology, 129, 86-91.
81. Younes, A., Romaguera, J., Hagemeister, F., McLaughlin, P., Rodriguez, M.A., Fiumara, P., Goy, A., Jeha, S., Manning, Jr, J.T., Jones, D., Abruzzo, L.V. & Medeiros, L.J. (2003) A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer, 98, 310-314.